CFO at Organogenesis (NASDAQ: ORGO) gets stock and option grants

Rhea-AI Filing Summary

Organogenesis Holdings Inc. reported that Chief Financial Officer Francisco David received equity awards and had shares withheld for taxes. He was granted a stock option for 111,358 shares with no exercise cost shown here, vesting in equal annual installments over four years beginning February 15, 2026. He also received 195,312 restricted stock units, each convertible into one share of Class A common stock as they vest annually over four years starting on the same date. In addition, 43,602 shares of Class A common stock were issued upon vesting of a 2025 performance share award tied to performance milestones, and 14,541 shares were disposed of at $3.84 per share to cover tax obligations. Following these transactions, he directly owned 731,020 Class A shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Francisco David

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A		195,312(1)	A	$0	701,959	D
Class A Common Stock	02/18/2026		A		43,602(2)	A	$0	745,561	D
Class A Common Stock	02/18/2026		F		14,541	D	$3.84	731,020	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.84	02/18/2026		A		111,358		(3)	02/18/2036	Class A Common Stock	111,358	$0	111,358	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026.

2. Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones.

3. The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.

	/s/ William R. Kolb, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Organogenesis (ORGO) CFO Francisco David report?

Organogenesis CFO Francisco David reported equity awards and a tax-related share disposition. He received a 111,358-share stock option, 195,312 restricted stock units, 43,602 performance-based shares, and had 14,541 shares withheld at $3.84 each to satisfy tax obligations.

How many Organogenesis (ORGO) stock options were granted to the CFO?

The CFO received a stock option covering 111,358 shares of Organogenesis Class A common stock. According to the disclosure, this option vests in equal annual installments over four years, beginning on February 15, 2026, providing long-term, performance-linked incentive compensation.

What is the vesting schedule for the Organogenesis (ORGO) RSUs granted to the CFO?

The RSU grant to the CFO totals 195,312 units, each representing one future share. These restricted stock units vest in equal annual installments over four years, starting on February 15, 2026, aligning executive compensation with multi-year company performance and continued service.

Why were 14,541 Organogenesis (ORGO) shares disposed of in this Form 4?

The 14,541 shares were disposed of to pay taxes related to share delivery. The filing labels this as a tax-withholding disposition at $3.84 per share, where shares are surrendered to cover tax liabilities rather than sold as a discretionary open-market transaction.

What performance-based shares did the Organogenesis (ORGO) CFO receive?

The CFO received 43,602 shares of Class A common stock from a 2025 performance share award. These shares were issued after the company determined that specified performance milestones had been achieved, converting the performance award into settled stock ownership for the executive.

How many Organogenesis (ORGO) shares does the CFO own after these transactions?

After the reported transactions, the CFO directly owns 731,020 shares of Organogenesis Class A common stock. This figure reflects the net result of new grants, performance share vesting, and shares withheld to satisfy tax obligations associated with his equity compensation.